Table 1: Clinical data and patient characteristics.

Anti-TNF responders ()Anti-TNF nonresponders ()Anti-IL-6R responders ()Newly diagnosed untreated RA ()

Mean age (range)57.2 (26–75)55.7 (29–71)57.5 (34–76)48.3 (22–67)#

Gender (female/male)19/1112/728/1511/8

Anti-TNF treatments30 (100.0)19 (100.0)
n (%) adalimumab10 (33.3)4 (21.1)
 Certolizumab6 (20.0)8 (42.1)
 Etanercept7 (23.3)4 (21.1)
 Infliximab4 (13.3)2 (10.5)
 Golimumab3 (10.0)1 (5.3)

Mean disease duration (range)11.3 (2–33) yrs10.8 (4–44) yrs12.0 (2–34) yrs2.7 (1–3) months
 Adalimumab11.9 (3–24)11.8 (5–19)
 Certolizumab10.7 (2–31)10.2 (4–44)
 Etanercept12.4 (2–33)11.0 (5–26)
 Infliximab13.5 (4–22)12.0 (5–19)
 Golimumab8.0 (3–16)9.0

Mean duration of current biological therapy months (range)29.8 (6–52)30.95 (6–50)33.0 (6–48)
 Adalimumab35.1 (6–52)30.8 (24–48)
 Certolizumab28.2 (8–42)29 (6–43)
 Etanercept26.7 (7–41)36.8 (18–50)
 Infliximab27.6 (10–33)22.5 (8–37)
 Golimumab31.4 (11–42)41

Prior use of TNF inhibitors3/306/1929/43
 No. of switching,
  n: 13/34/615/26
   22/69/26
   35/26

Patients on corticosteroid therapy n (%)8 (26.7)8 (42.1)15 (40.5)
 Adalimumab3/101/4
 Certolizumab1/63/8
 Etanercept2/72/4
 Infliximab2/41/2
 Golimumab0/31/1

Patients on conventional DMARD therapy n (%)26 (86.7)15 (79.0)23 (62.2)
 Adalimumab8/103/4
 Certolizumab5/66/8
 Etanercept6/73/4
 Infliximab4/42/2
 Golimumab3/31/1

ACPA positivity n (%)24 (85.4)14 (82.4)21 (41.4)19 (100.0)
 Adalimumab8/103/4
 Certolizumab5/66/8
 Etanercept5/72/4
 Infliximab3/42/2
 Golimumab3/31/1
DAS 28 score (mean ± SD)2.2 ± 0.85.12 ± 1.29+1.89 ± 0.877.71 ± 4.06#
 Adalimumab2.16 ± 0.794.64 ± 1.35
 Certolizumab2.09 ± 1.185.53 ± 0.82
 Etanercept1.70 ± 0.485.18 ± 1.98
 Infliximab3.00 ± 0.924.95 ± 0.27
 Golimumab2.36 ± 0.474.21 ± 0.00

between anti-TNF responders and IL-6R blocker responders. + between anti-TNF nonresponders and IL-6R blocker responders, # between newly diagnosed untreated RA group and all other groups. DMARD: disease-modifying antirheumatic drug; ACPA: anti-citrullinated protein antibody; DAS28: disease activity score with 28 joints; TNF: tumor necrosis factor alpha; IL-6R: interleukin-6 receptor.